|
Recent News
6/24/2010
EyeGate Pharma Initiates ALLUVION Phase III Study of EGP-437 in Patients with Dry Eye Syndrome
4/29/10
EyeGate Pharma Establishes Research Collaboration With GlaxoSmithKline to Deliver Medicines Using the EyeGate® II Delivery System
3/25/10
EyeGate Pharma Completes Phase II Study of EGP-437 in Patients with Anterior Uveitis
1/8/10
EyeGate Pharma Secures $22M in Series D Venture Funding for Continued Development of EGP-437 for Dry Eye Syndrome
Media Inquiries
Stephen From
CEO
Eyegate Pharmaceuticals
781.398.3820
sdfrom@eyegatepharma.com
|
